We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+33.39%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$163M
AUM Growth
+$47.2M
Cap. Flow
+$28.1M
Cap. Flow %
17.24%
Top 10 Hldgs %
69.1%
Holding
47
New
12
Increased
10
Reduced
9
Closed
14

Top Buys

Rank Stock Value
1
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$4.25M
2
XLRN
Acceleron Pharma
XLRN
+$3.94M
3
IMMU
Immunomedics Inc
IMMU
+$3.53M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$2.57M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.41M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$6.05M
2
GSK icon
GSK
GSK
+$5.48M
3
AMGN icon
Amgen
AMGN
+$4.57M
4
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$4.09M
5
LCI
Lannett Company, Inc.
LCI
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 69.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNCE
26
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.7M 1.04%
167,866
-15,134
-8% -$165K
SIOX
27
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$1.4M 0.86%
+12,500
New +$1.5M
FOMX
28
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.16M 0.71%
125,000
-20,250
-14% -$169K
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.11M 0.68%
+24,000
New +$1.35M
VTGN icon
30
VistaGen Therapeutics
VTGN
$9.45M
$575K 0.35%
4,604
– –
VSTM icon
31
Verastem
VSTM
$534M
$447K 0.27%
28,000
– –
NTBL
32
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$174K 0.11%
+952
New +$143K
TMBR
33
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$32K 0.02%
+4
New +$42.2K
AMGN icon
34
Amgen
AMGN
$203B
– –
-30,000
Closed -$4.57M
NERV icon
35
Minerva Neurosciences
NERV
$196M
– –
-13,375
Closed -$1.09M
PDSB icon
36
PDS Biotechnology
PDSB
$38.7M
– –
-6,792
Closed -$1.37M
QURE icon
37
uniQure
QURE
$2.63B
– –
-93,400
Closed -$688K
SCYX icon
38
SCYNEXIS
SCYX
$35.5M
– –
-3,438
Closed -$597K
VTRS icon
39
Viatris
VTRS
$20.5B
– –
-140,000
Closed -$6.05M
IMGN
40
DELISTED
Immunogen Inc
IMGN
– –
-140,500
Closed -$433K
ZYNE
41
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-57,100
Closed -$391K
AVEO
42
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
– –
-51,813
Closed -$498K
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-39,000
Closed -$974K
ARRY
44
DELISTED
Array Biopharma Inc
ARRY
– –
-521,000
Closed -$1.85M
RXDX
45
DELISTED
Ignyta, Inc.
RXDX
– –
-235,000
Closed -$1.27M
TBRA
46
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
– –
-75,000
Closed -$942K
CYNA
47
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
– –
-244,310
Closed -$4.09M
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Nexthera Capital held 47 positions worth $163M, up 41% from $115M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Nexthera Capital deployed $28.1M of net new capital in Q3 2016, opening 12 new positions and adding to 10 existing holdings. Its largest new stake was Immunomedics Inc: 1,263,276 shares worth $4.11M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was GSK, an estimated $5.48M trimmed.

  • Nexthera Capital's largest Q3 2016 buy was Immunomedics Inc: 1,263,276 shares worth $4.11M.
  • Nexthera Capital added most to Eiger BioPharmaceuticals, Inc. in Q3 2016, an estimated $4.25M increase.
  • Nexthera Capital's biggest Q3 2016 reduction was GSK, cutting an estimated $5.48M.
  • Nexthera Capital fully exited Viatris in Q3 2016, selling an estimated $6.05M.
  • Nexthera Capital's ten largest holdings make up 69% of its $163M portfolio in Q3 2016.
  • Nexthera Capital opened 12 new positions and closed 14 in Q3 2016.
  • Nexthera Capital's portfolio value rose 41% quarter-over-quarter to $163M.

Based on Nexthera Capital's 13F filing for Q3 2016, filed 14 Nov 2016.